By: Aleksey Ermachkov
Dr. Heather Brennan on the critical gap between scientific evidence and executive decision-making, and why the future of innovation depends on leaders who can bridge both worlds.
Scientific breakthroughs have the power to transform industries, reshape markets, and improve lives. Yet some of the most promising discoveries never reach their full potential. Not because the science is flawed, but because something essential gets lost between the laboratory and the boardroom.
For Dr. Heather Brennan, whose background spans engineering, scientific research, and executive leadership, this disconnect represents one of the most consequential challenges facing innovation-driven organizations today.
In an era when companies are under increasing pressure to innovate faster, demonstrate measurable results, and maintain a competitive advantage, the ability to translate scientific discovery into sound business decisions has become more than a technical skill. It is a leadership responsibility.
And according to Brennan, the challenge begins long before research findings reach an executive’s desk.
The problem isn’t always what the science tells us. It’s what happens to that information as it moves through an organization.
A scientific team may spend months or years investigating a question, testing variables, evaluating outcomes, and carefully documenting limitations. By the time those findings reach senior leadership, however, the complexity of the work has often been condensed into a presentation, a handful of performance indicators, or a recommendation to move forward.
In the process, critical context can disappear.
The conditions under which a result was achieved, the limitations of a study, the difference between statistical significance and commercial relevance, and the unanswered questions that remain may receive little attention. Yet these details can determine whether a promising discovery becomes a sustainable innovation or an expensive strategic mistake.
“A scientific result does not become valuable simply because it is impressive. Its value comes from understanding what the evidence actually supports, where its limitations are, and how responsibly that knowledge can be translated into a decision.” – Dr. Heather Brennan
Brennan’s perspective reflects a discipline deeply rooted in engineering: understanding not only whether something works, but why it works, under what conditions, and whether those conditions can be reproduced reliably.
That distinction matters enormously in business.
A product may demonstrate exceptional performance in a controlled environment but encounter entirely different variables when introduced into manufacturing, distribution, or everyday consumer use. A technology may deliver measurable improvements without yet having the evidence necessary to support broader commercial claims. An innovation may be scientifically promising but financially impractical at the scale a company intends to pursue.
None of these realities diminishes the underlying discovery. They simply demonstrate why scientific success and business readiness are not interchangeable.
For executives, the temptation is often to seek certainty. Leaders want to know whether an investment will deliver, whether a product will succeed, and whether the evidence justifies moving ahead.
But science rarely provides absolute certainty. It provides evidence of varying strength, shaped by methodology, sample size, conditions, and the questions researchers were originally trying to answer.
Effective leadership requires the ability to make decisions within that uncertainty rather than pretending it does not exist.
This is where Brennan believes the relationship between scientific and commercial teams must fundamentally evolve.
Too often, scientists are expected to present findings after the business has already determined what it wants to achieve. Research becomes a tool for validating an existing direction rather than informing which direction should be taken.
The stronger approach begins with collaboration before the research is designed.
What decision will these findings need to support? What level of evidence would justify moving forward? What risks would be unacceptable? What would cause leadership to reconsider its assumptions? And perhaps most importantly, what happens if the results do not support the original business objective?
These questions change the relationship between science and strategy. Instead of operating as separate departments with competing priorities, researchers and executives become partners in a shared decision-making process.
The most important scientific finding may be the one that challenges what leadership wants to believe.
In industries where innovation is closely tied to revenue, investment, and market positioning, there can be considerable pressure to emphasize favorable outcomes. Promising results become compelling headlines. Early observations are presented as established conclusions. Technical language is simplified until the distinction between possibility and proof becomes difficult to recognize.
This is not always the result of deliberate misrepresentation. Often, it emerges from the ordinary pressures of organizational communication.
Marketing teams need clear messages. Investors want compelling opportunities. Executives must make decisions within deadlines. Scientists, meanwhile, are trained to qualify their conclusions, acknowledge uncertainty, and distinguish observed results from broader interpretations.
The challenge is not choosing one perspective over the other. It is creating a decision-making culture in which commercial ambition and scientific integrity reinforce one another.
“One of the greatest risks in innovation is allowing the business objective to become more important than the evidence. Strong leadership means being willing to hear what the data is telling you, even when it complicates the plan.” – Dr. Heather Brennan
This philosophy has implications far beyond research-intensive businesses.
As artificial intelligence accelerates data analysis, product development, and executive reporting, organizations can produce sophisticated insights at unprecedented speed. But faster analysis does not automatically create better judgment.
An AI-generated summary may identify patterns without fully explaining the limitations of the underlying data. A performance dashboard may highlight growth without revealing whether that growth is sustainable. A predictive model may produce an apparently precise recommendation while relying on assumptions that deserve closer scrutiny.
Technology can make information more accessible. It cannot eliminate the responsibility to question how that information was produced and what conclusions it can reasonably support.
For Brennan, this reinforces the importance of leaders who possess both technical literacy and strategic perspective.
Executives do not need to become scientists. They do, however, need to become better consumers of scientific information.
That means asking whether findings have been independently validated, understanding the difference between correlation and causation, recognizing when results are preliminary, and evaluating whether the evidence applies to the population, application, or market being considered.
It also means creating an environment where researchers can communicate unfavorable findings without fearing that transparency will be interpreted as failure.
A study that reveals a limitation can prevent a costly launch. An experiment that challenges a hypothesis can redirect resources toward a stronger opportunity. A researcher who identifies an overlooked variable can protect an organization from reputational, regulatory, or financial consequences.
These are not setbacks to innovation. They are part of the process that makes innovation credible.
There is also a financial argument for getting this relationship right.
Organizations invest substantial resources in research and development, but the return on that investment depends on more than the quality of the underlying discovery. It depends on whether leaders can recognize the appropriate applications, understand the associated risks, allocate capital intelligently, and distinguish genuine opportunity from enthusiasm.
When scientific teams and executive leadership operate without a shared understanding of evidence, businesses risk investing too heavily in premature ideas while overlooking discoveries with greater long-term potential.
The cost is not limited to wasted resources. It can include lost credibility, weakened consumer trust, and missed opportunities to develop innovations that deliver meaningful value.
The companies best positioned to navigate this challenge will not necessarily be those producing the largest volume of research or moving products to market the fastest. They will be those capable of making the strongest decisions from the evidence available.
That requires a different kind of organizational discipline.
Scientific findings must be communicated in language that decision-makers can understand without sacrificing their meaning. Commercial teams must articulate the questions they need answered rather than simply requesting supporting data. And senior leaders must recognize that the most responsible decision is sometimes to delay, investigate further, or change direction.
“The real measure of leadership is not how quickly you can turn a discovery into a commercial opportunity. It is whether you can preserve the integrity of that discovery while building something that creates lasting value.” – Dr. Heather Brennan
Ultimately, Brennan’s perspective raises a larger question about what modern executive leadership should look like.
For decades, technical expertise and commercial leadership have often been treated as distinct disciplines. Scientists were responsible for discovery. Business leaders were responsible for execution. The handoff between the two was assumed to be a relatively straightforward process of communicating results and determining next steps.
Today’s innovation economy is exposing the limitations of that model.
The challenges facing organizations are increasingly interdisciplinary. Scientific advancement intersects with regulation, consumer expectations, financial strategy, technological development, and public trust. Decisions made in one area can have profound consequences in another.
Leaders who understand these intersections have an opportunity to build organizations that are not only more innovative but also more resilient.
They can ask better questions before committing resources. They can recognize when evidence is being overstated. They can foster productive tension between scientific caution and commercial ambition without allowing either to dominate the conversation.
Most importantly, they can establish a culture in which intellectual honesty is viewed as a competitive advantage rather than an obstacle to growth.
The future of innovation will not be determined solely by what scientists discover.
It will also be determined by what business leaders understand, what they choose to question, and what they ultimately decide to do with the knowledge placed before them.
The distance between discovery and decision may seem small on an organizational chart. In practice, it can determine whether an innovation changes an industry or becomes another missed opportunity.
And closing that distance may be one of the most important responsibilities of executive leadership today.
